Atara Biotherapeutics Inc. said Isaac Ciechanover has decided to step down as president and CEO.
Ciechanover will keep serving at Atara Biotherapeutics until June 30 or until the appointment of a replacement. He became president and CEO of Atara Biotherapeutics in August 2012.
The company's board has formed a search committee to evaluate candidates for the CEO position.
Atara develops cancer treatments. Its most advanced T cell immunotherapy, tab-cel, is being studied for treating patients with Epstein-Barr virus associated with a post-transplant lymphoproliferative disorder as well as other EBV-associated hematologic and solid tumors, including nasopharyngeal carcinoma.